These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28694540)

  • 1. Adherence to uptake of magnesium sulphate for neuroprotection in preterm births <30 weeks at Christchurch Hospital.
    Pang J
    N Z Med J; 2017 Jul; 130(1458):52-53. PubMed ID: 28694540
    [No Abstract]   [Full Text] [Related]  

  • 2. Survey on use of antenatal magnesium sulphate for fetal neuroprotection prior to preterm birth in Australia and New Zealand - Ongoing barriers and enablers.
    Gatman K; May R; Crowther C
    Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):44-48. PubMed ID: 31119725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnesium sulfate for preterm neuroprotection.
    Mittendorf R; Lee KS; Roizen NJ; Pryde PG
    JAMA; 2004 Feb; 291(8):940-1; author reply 941. PubMed ID: 14982906
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evidence exists for prophylactic magnesium sulphate as a neuroprotector in premature births].
    Wolf HT; Hegaard HK; Huusom L; Greisen G; Hedegaard M
    Ugeskr Laeger; 2011 Mar; 173(13):962-5. PubMed ID: 21453636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
    Crowther CA; Hiller JE; Doyle LW; Haslam RR;
    JAMA; 2003 Nov; 290(20):2669-76. PubMed ID: 14645308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuroprotection for preterm infants with antenatal magnesium sulphate].
    Marret S; Ancel PY
    J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1418-1433. PubMed ID: 28166926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective audit of the adherence to a new magnesium sulphate guideline for the neuroprotection of infants born less than 30 weeks' gestation.
    Tan YH; Groom KM
    Aust N Z J Obstet Gynaecol; 2015 Feb; 55(1):90-3. PubMed ID: 25307153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnesium sulphate for the prevention of cerebral palsy in Australia and New Zealand.
    Bain E; Goodchild L; Lontis R; McIntyre S; Ashwood P; Bubner T; Middleton P; Crowther C
    Aust Nurs J; 2013 Jul; 21(1):34-7. PubMed ID: 23930314
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonreceipt of antenatal magnesium sulphate for fetal neuroprotection at the Women's and Children's Hospital, Adelaide 2010-2013.
    Siwicki K; Bain E; Bubner T; Ashwood P; Middleton P; Crowther CA
    Aust N Z J Obstet Gynaecol; 2015 Jun; 55(3):233-8. PubMed ID: 26084194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risks of extending the controversial use of tocolytic magnesium sulfate for the purpose of neuroprotection in preterm labor.
    Mittendorf R; Roizen NJ; Pryde PG
    J Perinatol; 2004 Jul; 24(7):465-6. PubMed ID: 15224123
    [No Abstract]   [Full Text] [Related]  

  • 11. Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial.
    Wolf HT; Brok J; Henriksen TB; Greisen G; Salvig JD; Pryds O; Hedegaard M; Weber T; Hegaard HK; Pinborg A; Huusom LD;
    BJOG; 2020 Sep; 127(10):1217-1225. PubMed ID: 32237024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Working to improve survival and health for babies born very preterm: the WISH project protocol.
    Crowther CA; Middleton PF; Bain E; Ashwood P; Bubner T; Flenady V; Morris J; McIntyre S;
    BMC Pregnancy Childbirth; 2013 Dec; 13():239. PubMed ID: 24354790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection.
    Magee L; Sawchuck D; Synnes A; von Dadelszen P; ;
    J Obstet Gynaecol Can; 2011 May; 33(5):516-529. PubMed ID: 21639972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnesium sulfate for neuroprotection in the setting of chorioamnionitis.
    Edwards JM; Edwards LE; Swamy GK; Grotegut CA
    J Matern Fetal Neonatal Med; 2018 May; 31(9):1156-1160. PubMed ID: 28395549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal adverse effects with different loading infusion rates of antenatal magnesium sulphate for preterm fetal neuroprotection: the IRIS randomised trial.
    Bain ES; Middleton PF; Yelland LN; Ashwood PJ; Crowther CA
    BJOG; 2014 Apr; 121(5):595-603. PubMed ID: 24387624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium sulfate for neuroprotection in patients at risk for early preterm delivery: not yet.
    Sibai BM
    Am J Obstet Gynecol; 2011 Oct; 205(4):296-7. PubMed ID: 22083053
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of intravenous magnesium in non-preeclamptic pregnant women: fetal/neonatal neuroprotection.
    Jacquemyn Y; Zecic A; Van Laere D; Roelens K
    Arch Gynecol Obstet; 2015 May; 291(5):969-75. PubMed ID: 25501980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: a study using the theoretical domains framework.
    Bain E; Bubner T; Ashwood P; Van Ryswyk E; Simmonds L; Reid S; Middleton P; Crowther CA
    BMC Pregnancy Childbirth; 2015 Aug; 15():176. PubMed ID: 26283623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate clinical outcomes in preterm neonates receiving antenatal magnesium for neuroprotection.
    Basu SK; Chickajajur V; Lopez V; Bhutada A; Pagala M; Rastogi S
    J Perinat Med; 2011 Aug; 40(2):185-9. PubMed ID: 21834608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of implementing magnesium sulphate for neuroprotection in a tertiary obstetric unit.
    Ow LL; Kennedy A; McCarthy EA; Walker SP
    Aust N Z J Obstet Gynaecol; 2012 Aug; 52(4):356-60. PubMed ID: 22515404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.